Metrodora Institute Announces Healthcare and Biotech Leader, John B. Wirthlin, as CEO

Wirthlin also appointed to Metrodora’s Board of Directors

SALT LAKE CITY--(BUSINESS WIRE)-- Metrodora Institute, an innovative medical and research center dedicated to advancing care, treatments, and cures for people living with complex, chronic diseases, today announced that it has appointed John B. Wirthlin as Chief Executive Officer. As part of his responsibilities, Wirthlin will also join the company’s Board of Directors. A healthcare and biotech industry veteran, Wirthlin has spent more than 18 years leading innovative healthcare companies. Laura A. Pace, MD, PhD, Co-founder of Metrodora Institute, will continue to serve on the company’s Board of Directors.

“My co-founders and I are excited to welcome John to the Metrodora team,” said Laura A. Pace, MD, PhD, Metrodora Institute Co-founder. “The whole team looks forward to working with John to achieve Metrodora’s bold mission of advancing care and accelerating cures for neuroimmune axis disorders. As a physician-scientist, I am excited to lead Metrodora’s efforts to drive medical innovation and scientific discovery, so that we can truly realize our dream of developing better diagnostics, therapeutics and ultimately cures for these complex disorders that devastate millions of American families.”

Wirthlin joins Metrodora Institute from Lumea, a digital pathology company revolutionizing the practice and delivery of diagnostic medicine. Prior to Lumea, Wirthlin served as CEO of AlloCure, a biotech company developing new cell therapies for kidney disease.

“Dr. Pace and the founding team launched Metrodora Institute with a bold vision to pioneer something entirely new in an industry that has long been slow to innovate,” said Mr. Wirthlin. “I have spent much of my professional career deploying technologies and processes that break down traditional healthcare silos to improve patient care. Today, Metrodora has an incredible opportunity to become the bridge connecting many of these siloed sectors to make dramatic improvements in how we diagnose and treat patients with complex, chronic diseases. I look forward to partnering with Dr. Pace and the team on realizing Metrodora’s full potential.”

Aaron Gerszewski, Managing Partner at Wasatch Equity Partners and Metrodora board participant, added: “In launching Metrodora Institute, Dr. Pace and the Metrodora team have done what many considered impossible. We believe that John, as an experienced operator and creative problem solver, will be effective in leading Metrodora through this pivotal next chapter of growth. We are excited to continue supporting the Institute as they transform healthcare for chronic illnesses through an innovative and collaborative care model in the coming years.”

Founded in 2020, Metrodora Institute aims to deliver a new blueprint for patient care designed to break down the silos between scientific research and medical practice. Today, the Company is leading the next frontier of science and medicine to address a significant and unmet medical need.

About Metrodora Institute

Metrodora Institute is an innovative medical and research center dedicated to advancing care and accelerating the discovery of cures for people living with complex, chronic conditions known as neuroimmune axis disorders. Located in Salt Lake City, UT, the integrated multidisciplinary institute brings together world-class clinicians, scientists, and engineers under one roof – to maximize the impact of scientific discovery and rapidly translate research into better human health outcomes. Metrodora’s comprehensive clinical programs integrate neurology, immunology, and gastroenterology care with genomics, pain management, comprehensive rehabilitation programs, nutritional and neurocognitive therapies, and telehealth services to provide patient-centered care. Grounded in multidisciplinary collaboration, Metrodora is delivering a new blueprint for patient care, designed to break down silos between scientific research and medical practice. Learn more at www.metrodora.co

View source version on businesswire.com: https://www.businesswire.com/news/home/20230830736216/en/